ct candidates. As part of that transaction, Alexza licensed to Symphony Allegro its
Staccato loxapine program and its
Staccato alprazolam program. Since that time, Alexza has been conducting the clinical development of AZ-004 for the acute treatment of agitation, AZ-104 for the acute treatment of migraine headache, and AZ-002 for the treatment of acute panic attacks, with the funds provided by Symphony Allegro.
"In the past 30 months, we have conducted 14 clinical trials with the three product candidates that were licensed into Symphony Allegro. This is a remarkable development achievement, by almost any standard. Moreover, we plan to submit Alexza's first NDA for AZ-004, Staccato loxapine, in the first quarter of 2010. Symphony Capital and RRD International have been a very important part of these accomplishments," said Thomas B. King, Alexza President and CEO. "With the closing of the purchase of Symphony Allegro, we will re-acquire full ownership of AZ-004, AZ-104 and AZ-002. In our partnership with Symphony Allegro, the intended development of these product candidates has been achieved and, assuming our stockholders approve the transaction, Symphony Capital and its investors will be able to share in the future benefits of the advancement of these product candidates."
Mark Kessel, Managing Director of Symphony Capital, added, "We are pleased to have been a part of this collaboration which provided capital and development assistance to enable Alexza to advance these product candidates to the point they are today. The terms of the agreement we have announced today continue to reflect the confidence that we have in Alexza and its management."
Conference Call Information
Alexza will host a conference call tomorrow morning, June 16, 2009, at 9:00 a.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call, replay and w
'/>"/>
SOURCE Alexza Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine news :1.
Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 20082.
Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System3.
Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference4.
Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.5.
Alexza to Webcast Investor and Analyst Day Presentations6.
Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference7.
Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality8.
Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.9.
Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations10.
Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 200811.
Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates